Abstract
purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p
| Original language | English |
|---|---|
| Pages (from-to) | 171-178 |
| Number of pages | 8 |
| Journal | American Journal of Medicine |
| Volume | 90 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1991 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Nursing(all)
Cite this
Effect of progestin therapy on cortical and trabecular bone : comparison with estrogen. / Gallagher, John Christopher G.; Kable, Warren T.; Goldgar, David.
In: American Journal of Medicine, Vol. 90, No. 1, 1991, p. 171-178.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effect of progestin therapy on cortical and trabecular bone
T2 - comparison with estrogen
AU - Gallagher, John Christopher G.
AU - Kable, Warren T.
AU - Goldgar, David
PY - 1991
Y1 - 1991
N2 - purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p
AB - purpose: To determine the effect of progestin therapy on bone mineral density in postmenopausal women and to compare its effects to those of estrogen. subjects and methods: A prospective, randomized clinical trial was performed in 81 postmenopausal women aged 51.7 ± 4.4 years (mean ± SD). They were assigned to one of four groups: Provera® 20 mg, Premarin® 0.6 mg, Premarin 0.3 mg plus Provera 10 mg, and a placebo. In addition, all women received calcium supplementation, if necessary, to a calcium intake of 1,000 mg/day. We used single- and dual-photon absorpiometry, metacarpal radiogrammetry, and computed axial tomography to measure bone mineral density in the total skeleton, spine, radius, and metacarpal. results: Women receiving placebo lost bone at all sites (p
UR - http://www.scopus.com/inward/record.url?scp=0025905957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025905957&partnerID=8YFLogxK
U2 - 10.1016/0002-9343(91)90538-9
DO - 10.1016/0002-9343(91)90538-9
M3 - Article
VL - 90
SP - 171
EP - 178
JO - American Journal of Medicine
JF - American Journal of Medicine
SN - 0002-9343
IS - 1
ER -